Cor Vasa 2013, 55(4):e397-e402 | DOI: 10.1016/j.crvasa.2013.07.006
Hypertension and chronic kidney diseases
- a Interní klinika, 1. lékařská fakulta Univerzity Karlovy a Ústřední vojenská nemocnice, Praha, Česká republika
- b Nefrologická ambulance, Synlab, s. r. o., Praha, Česká republika
Chronic kidney diseases - arising from inborn or acquired renal disorders - are one of the most common causes of secondary hypertension. Renal parenchymatous hypertension accompanying bilateral or unilateral kidney diseases is more prevalent than renovascular hypertension. The prevalence and severity of hypertension are influenced by age, weight, type of renal affliction, and depth of renal dysfunction. In multifactorial pathogenesis, sodium retention plays the crucial role together with dysbalance concerning effects of different vasoactive substances; however, unequivocal distinction between volume- and renin-type hypertension is difficult. The treatment of renal hypertension includes appropriate lifestyle changes, pharmacotherapy, hemoelimination methods and radiological or urological invasive procedures. In chronic kidney diseases with increased albuminuria or proteinuria, ACE inhibitors and AT1-blockers are preferred. Combination of several antihypertensives is often required to achieve the target blood pressure. Increased blood pressure represents not only the manifestation of chronic kidney diseases but also an important factor concerning the renal and cardiovascular risk.
Keywords: Chronic kidney disease; Pharmacotherapy; Progression; Renal hypertension; Target blood pressure
Received: July 1, 2013; Revised: July 17, 2013; Accepted: July 23, 2013; Published: August 1, 2013 Show citation
References
- J. Coresh, E. Selvin, L.A. Stevens, et al., Prevalence of chronic kidney disease in the United States, The Journal of the American Medical Association 298 (2007) 2038-2047.
Go to original source...
Go to PubMed...
- L. Zhang, P. Zhang, F. Wang, et al., Prevalence and factors associated with CKD: a population study from Beijing, American Journal of Kidney Diseases 51 (2008) 373-384.
Go to original source...
Go to PubMed...
- S.J. Chadban, E.M. Briganti, P.G. Kerr, et al., Prevalence of kidney damage in Australian adults: The AusDiab kidney study, Journal of the American Society of Nephrology 14 (Suppl 2) (2003) S131-S138.
Go to original source...
Go to PubMed...
- D.E. Weiner, Public health consequences of chronic kidney disease, Clinical Pharmacology and Therapeutics 86 (2009) 566-569.
Go to original source...
Go to PubMed...
- KDIGO Blood Pressure Group, KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease, Kidney International Supplements 2 (5) (2012) 337-414.
- KDIGO CKD Work Group, KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, Kidney International Supplements 3 (1) (2013) 1-150.
- National Kidney Foundation, K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, American Journal of Kidney Diseases 39 (Suppl 2) (2002) S1-S266.
- A.S. Levey, J. Coresh, E. Balk, et al., National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification, Annals of Internal Medicine 139 (2003) 137-147.
Go to original source...
- N.M. Kaplan, Kaplan's clinical hypertension, 9th ed., Lippincott Williams & Wilkins, Philadelphia, 2006 (518 pp).
- V. Monhart, Hypertenze a ledviny, 2. rozšířené a přepracované vydání, Triton, Praha, 2007.
- T. Seeman, Měření krevního tlaku a diagnostika a léčba hypertenze v pediatrii, in: J. Janda, H. Cabrnochová (eds.), Klinická pediatrie, Postgraduální medicína 8 (Suppl) (2006) 12-22.
- A.T. Whaley-Connell, J.R. Sowers, L.A. Stevens, et al., CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004, American Journal of Kidney Diseases 51 (2008) S13-S20.
Go to original source...
Go to PubMed...
- J. Neumann, G. Ligtenberg, I.I. Klein, et al., Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment, Kidney International 65 (2004) 1568-1576.
Go to original source...
Go to PubMed...
- J. Passauer, F. Pistrosch, E. Büssemaker, et al., Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide, Journal of the American Society of Nephrology 16 (2005) 959-965.
Go to original source...
Go to PubMed...
- NKF, K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease, American Journal of Kidney Diseases 43 (2004) S1-S290.
Go to original source...
- A. Upadhyay, A. Earley, S.M. Haynes, K. Uhlig, Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier, Annals of Internal Medicine 154 (2011) 541-548.
Go to original source...
Go to PubMed...
- D.C. Wheeler, G.J. Becker, Summary of KDIGO Guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?, Kidney International 83 (2013) 377-383.
Go to original source...
Go to PubMed...
- G.L. Bakris, M.R. Weir, M. Secic, et al. Differential effects of calcium antagonist subclasses on markers nephropathy progression, Kidney International 65 (2004) 1991-2002.
Go to original source...
Go to PubMed...
- M. Nedbálková, M. Souček, Léčba hypertenze u dialyzovaných, Interní medicína pro praxi 9 (2007) 319-323.
- H.J.L. Heerspink, T. Ninomiya, S. Zoungas, et al., Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials, Lancet 373 (2009) 1009-1015.
Go to original source...
Go to PubMed...
- N.W. Levin, P. Kotanko, K.U. Eckardt, et al., Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference, Kidney International 77 (2010) 273-284.
Go to original source...
Go to PubMed...
- J.M. Alcazar, J.L. Rodicio, How to handle renovascular hypertension, in: J. Gajkowska (ed.), ESH Clinical Practice Newsletters, VM Group, Gdaňsk, 2011; pp. 9-10.
- B.L. Jaber, N.E. Madias, Progression of chronic kidney disease: can it be prevented or arrested?, American Journal of Medicine 118 (2005) 1323-1330.
Go to original source...
Go to PubMed...
- M.W. Taal, B.M. Brenner, Predicting initiation and progression of chronic kidney disease: developing renal risk scores, Kidney International 70 (2006) 1694-1705.
Go to original source...
Go to PubMed...
- M.W. Taal, B.M. Brenner, Renal risk scores: progress and prospects, Kidney International 73 (2008) 1216-1219.
Go to original source...
Go to PubMed...
- T.H. Jafar, P.C. Stark, C.H. Schmid, et al., Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis, Annals of Internal Medicine 139 (2003) 244-252.
Go to original source...
Go to PubMed...
- P. Ruggenenti, A. Fassi, A.P. Ilieva, et al., Preventing microalbuminuria in type 2 diabetes, The New England Journal of Medicine 351 (2004) 1941-1951.
Go to original source...
Go to PubMed...
- H.H. Parving, H. Lehnert, J. Brochner-Mortensen, et al., The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes, The New England Journal of Medicine 345 (2001) 870-878.
Go to original source...
Go to PubMed...
- B.M. Brenner, M.E. Coper, D. deZeeuw, et al., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, The New England Journal of Medicine 345 (2001) 861-869.
Go to original source...
Go to PubMed...
- E.J. Lewis, L.G. Hunsicker, W.R. Clarke, et al., Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, The New England Journal of Medicine 345 (2001) 851-860.
Go to original source...
Go to PubMed...